Ahmed Zahra
Antibody-Drug Conjugates (ADCs) have emerged as a promising class of therapeutics in immuno-oncology, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This brief study explores the role of ADCs in immuno-oncology, focusing on their potential for combination approaches to enhance therapeutic responses. By leveraging the unique characteristics of ADCs and synergizing with other immuno-oncology modalities, such as immune checkpoint inhibitors and adoptive cell therapies, ADCs hold the promise of improving outcomes for cancer patients
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi